IMED Biotech Unit (Oncology)
Mark is Chief Scientist in AstraZeneca's Oncology IMED in Cambridge, UK, heading up the DNA Damage Response (DDR) biology area. This involves leading the strategy to identify and develop inhibitors of DDR to generate new medicines for cancer patients. The current portfolio includes one approved product, two agents in clinical trials and an ATM inhibitor due to enter the clinic in 2015. Mark is also lead scientist for AstraZeneca’s recently approved PARP inhibitor and AZD1775, a WEE1 inhibitor in Phase II. A key component of the DDR strategy was the in-licensing of the WEE1 inhibitor AZD1775 from Merck in late 2013.